{"id":63111,"date":"2026-04-14T20:30:49","date_gmt":"2026-04-14T12:30:49","guid":{"rendered":"https:\/\/flcube.com\/?p=63111"},"modified":"2026-04-14T20:30:50","modified_gmt":"2026-04-14T12:30:50","slug":"tasly-pharma-partners-with-beijing-neurosurgical-institute-on-dual-target-car-t-therapy-rmb-240m-investment-advances-cd44-cd133-autologous-treatment-for-recurrent-glioblastoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63111","title":{"rendered":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma"},"content":{"rendered":"\n<p><strong>Tasly Pharma Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600535:SHA\">SHA: 600535<\/a>) announced plans to enter a <strong>collaboration agreement<\/strong> with the <strong>Beijing Neurosurgical Institute<\/strong> and <strong>Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd<\/strong> to jointly advance the development and industrialization of a <strong>dual-target CAR-T therapy<\/strong> for <strong>recurrent glioblastoma<\/strong>. The autologous CAR-T product, targeting <strong>CD44 and\/or CD133<\/strong>, received <strong>clinical trial approval in April 2025<\/strong> and has already initiated <strong>Phase I clinical studies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-financial-framework\">Partnership Structure &amp; Financial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Developer<\/strong><\/td><td>Tasly Pharma Co., Ltd (SHA: 600535)<\/td><\/tr><tr><td><strong>Technology Holder<\/strong><\/td><td>Beijing Neurosurgical Institute<\/td><\/tr><tr><td><strong>R&amp;D Partner<\/strong><\/td><td>Beijing Rencheng Neurotumor Biotechnology Engineering Research Center<\/td><\/tr><tr><td><strong>Total R&amp;D Investment<\/strong><\/td><td>RMB 240 million (USD 35.2 million)<\/td><\/tr><tr><td><strong>Cost Sharing<\/strong><\/td><td>Proportional allocation based on responsibilities and development stages<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I clinical trials (initiated)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-status\">Product Profile &amp; Clinical Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapy Type:<\/strong> Autologous CAR-T cell therapy<\/li>\n\n\n\n<li><strong>Targets:<\/strong> CD44 and\/or CD133 \u2013 dual-target approach for enhanced tumor specificity<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Recurrent glioblastoma \u2013 one of the most aggressive and treatment-resistant brain cancers<\/li>\n\n\n\n<li><strong>Regulatory Milestone:<\/strong> Clinical trial approval granted April 2025 by NMPA<\/li>\n\n\n\n<li><strong>Current Status:<\/strong> Phase I clinical studies actively enrolling patients<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Addresses critical gap in recurrent glioblastoma treatment with median survival of 6\u20139 months post-recurrence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-role-allocation-amp-commercial-rights\">Role Allocation &amp; Commercial Rights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tasly-pharma-responsibilities\">Tasly Pharma Responsibilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Marketing Authorization Holder (MAH)<\/strong> status<\/li>\n\n\n\n<li>Lead all R&amp;D coordination and regulatory filing activities<\/li>\n\n\n\n<li>Full commercialization strategy and execution<\/li>\n\n\n\n<li><strong>Exclusive ownership<\/strong> of manufacturing and commercial rights<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-beijing-neurosurgical-institute-role\">Beijing Neurosurgical Institute Role<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core technology holder<\/strong> with patent ownership<\/li>\n\n\n\n<li>Ongoing R&amp;D support and scientific guidance<\/li>\n\n\n\n<li>Clinical expertise in neurosurgical oncology applications<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-beijing-rencheng-bio-contribution\">Beijing Rencheng Bio Contribution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Technical and financial support for specific R&amp;D stages<\/li>\n\n\n\n<li>Risk-sharing partnership model<\/li>\n\n\n\n<li><strong>Profit participation<\/strong> proportional to actual R&amp;D investment alongside Tasly<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR-T Market Entry:<\/strong> Positions Tasly as a serious player in China&#8217;s emerging cell therapy market<\/li>\n\n\n\n<li><strong>Neuro-Oncology Focus:<\/strong> Addresses high-value, high-unmet-need indication with limited therapeutic options<\/li>\n\n\n\n<li><strong>Dual-Target Innovation:<\/strong> CD44\/CD133 targeting may overcome limitations of single-target CAR-T approaches in solid tumors<\/li>\n\n\n\n<li><strong>Industrialization Pathway:<\/strong> Clear commercial rights structure enables efficient scale-up and market access planning<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glioblastoma Market:<\/strong> Global recurrent glioblastoma market estimated at $1.2 billion annually with premium pricing potential for effective therapies<\/li>\n\n\n\n<li><strong>China Cell Therapy Landscape:<\/strong> Growing regulatory support for advanced therapy medicinal products (ATMPs) with expedited pathways for innovative approaches<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Among the first dual-target CAR-T therapies specifically developed for glioblastoma in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p>The RMB 240 million investment represents a strategic allocation of capital toward high-value oncology innovation. Tasly maintains full commercial control while sharing development risk through the collaborative partnership structure.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations for the dual-target CAR-T therapy. Actual results may differ due to risks inherent in cell therapy development, including clinical trial outcomes, manufacturing challenges, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600535_20260320_RVIX.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600535_20260320_RVIX.\"><\/object><a id=\"wp-block-file--media-b3e36502-b3b0-4ad5-8546-219fbeca8d3a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600535_20260320_RVIX.pdf\">600535_20260320_RVIX<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600535_20260320_RVIX.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b3e36502-b3b0-4ad5-8546-219fbeca8d3a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,1211,433],"class_list":["post-63111","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-car-t","tag-sha-600535","tag-tasly-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63111\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma\" \/>\n<meta property=\"og:description\" content=\"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63111\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T12:30:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T12:30:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\\\/CD133 Autologous Treatment for Recurrent Glioblastoma\",\"datePublished\":\"2026-04-14T12:30:49+00:00\",\"dateModified\":\"2026-04-14T12:30:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CAR-T\",\"SHA: 600535\",\"Tasly Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63111#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63111\",\"name\":\"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\\\/CD133 Autologous Treatment for Recurrent Glioblastoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T12:30:49+00:00\",\"dateModified\":\"2026-04-14T12:30:50+00:00\",\"description\":\"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\\\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63111\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63111#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\\\/CD133 Autologous Treatment for Recurrent Glioblastoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma - Insight, China&#039;s Pharmaceutical Industry","description":"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63111","og_locale":"en_US","og_type":"article","og_title":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma","og_description":"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.","og_url":"https:\/\/flcube.com\/?p=63111","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T12:30:49+00:00","article_modified_time":"2026-04-14T12:30:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63111#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63111"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma","datePublished":"2026-04-14T12:30:49+00:00","dateModified":"2026-04-14T12:30:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63111"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CAR-T","SHA: 600535","Tasly Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63111#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63111","url":"https:\/\/flcube.com\/?p=63111","name":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T12:30:49+00:00","dateModified":"2026-04-14T12:30:50+00:00","description":"Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and\/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63111#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63111"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63111#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy \u2013 RMB 240M Investment Advances CD44\/CD133 Autologous Treatment for Recurrent Glioblastoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63111"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63111\/revisions"}],"predecessor-version":[{"id":63113,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63111\/revisions\/63113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}